Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock investor conference presentation 9/26/2019 Hoth Therapeutics (NASDAQ: HOTH) is targeting multi-billion dollar market opportunities, with it’s pipeline of targeted dermatological therapies for eczema, psoriasis, chronic wound disorders, […]
Company in position for pre-sales license inspection, last step to issuance of a Sales License FSD Pharma Inc. (“FSD Pharma” or the “Company”) (OTC: FSDDF) (cse:HUGE)(fra:0K9) is pleased to announce that its wholly-owned subsidiary, FV […]
The Yield Growth Corp. (CSE: BOSS) (OTC: BOSQF) interview with CEO, Penny Green, sharing an update on the company’s expanding retail and online distribution of it’s Urban Juve hemp- […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
